Title:
PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND LOBEGLITAZONE
Document Type and Number:
WIPO Patent Application WO/2017/073897
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical composition comprising metformin or a pharmaceutically acceptable salt thereof and lobeglitazone or a pharmaceutically acceptable salt thereof and a pharmaceutical formulation comprising the same. The pharmaceutical composition can exhibit a synergistic effect on glycemic control and can block the potential of side effects, and the pharmaceutical formulation can be provided in the form of a combination formulation that is able to be administered once a day to thus improve medication compliance.
Inventors:
SHIN EUN JI (KR)
CHO MIN KWAN (KR)
SHIN TEAK HWAN (KR)
PARK SHIN JUNG (KR)
LIM JONG RAE (KR)
CHO MIN KWAN (KR)
SHIN TEAK HWAN (KR)
PARK SHIN JUNG (KR)
LIM JONG RAE (KR)
Application Number:
PCT/KR2016/009393
Publication Date:
May 04, 2017
Filing Date:
August 24, 2016
Export Citation:
Assignee:
CHONG KUN DANG PHARMACEUTICAL CORP (KR)
International Classes:
A61K31/155; A61K9/28; A61K31/426; A61K31/506; A61K47/38
Foreign References:
| KR20130039344A | 2013-04-19 | |||
| KR100812538B1 | 2008-03-11 | |||
| KR20040079898A | 2004-09-16 |
Other References:
SHIN, D. ET AL.: "Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.", CURRENT MEDICAL RESEARCH AND OPINION, vol. 28, no. 7, 2012, pages 1213 - 1220
JIN, S.-M. ET AL.: "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.", DIABETES, OBESITY AND METABOLISM, vol. 17, no. 6, June 2015 (2015-06-01), pages 599 - 602
JIN, S.-M. ET AL.: "Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.", DIABETES, OBESITY AND METABOLISM, vol. 17, no. 6, June 2015 (2015-06-01), pages 599 - 602
Attorney, Agent or Firm:
AHN, So Young (KR)
Download PDF:
Previous Patent: AIR CONDITIONER
Next Patent: PLASTICIZATION TYPE COSMETIC COMPOSITION USING VOLATILE OIL AS SOLVENT AND PREPARATION METHOD THEREF...
Next Patent: PLASTICIZATION TYPE COSMETIC COMPOSITION USING VOLATILE OIL AS SOLVENT AND PREPARATION METHOD THEREF...